Expression of RECK in endothelial cells of glioma: Comparison with CD34 and VEGF expressions

Journal of Neuro-Oncology

Volumn 107, Issue 3, 2012, Pages 559-564

  Rahmah, Nunung Nur ^a   Sakai, Keiichi ^a,b   Sano, Kenji ^c   Hongo, Kazuhiro ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shinshu Ueda Medical Center   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

CD34; Glioma; Microvascular density; RECK; VEGF

Indexed keywords

CD34 ANTIGEN; PROTEIN; RECK PROTEIN; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG; VASCULOTROPIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; RECK PROTEIN, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GRADING; CANCER TISSUE; CORRELATION ANALYSIS; CYTOPLASM; DRUG TARGETING; ENDOTHELIUM CELL; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROVASCULATURE; MICROVESSEL DENSITY; PROTEIN EXPRESSION; STAINING; TUMOR CELL; BIOSYNTHESIS; BRAIN TUMOR; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANTIGENS, CD34; BRAIN NEOPLASMS; ENDOTHELIAL CELLS; GLIOMA; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864375708     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0778-z     Document Type: Article

References (27)

1. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T, Noda M (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95:13221-13226
2. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M (2001) The membraneanchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107:789-800
3. Miki T, Takegami Y, Okawa K, Muraguchi T, Noda M, Takahashi C (2007) The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways. J Biol Chem 282:12341-12352
4. Omura A, Matsuzaki T, Mio K, Ogura T, Yamamoto M, Fujita A, Okawa K, Kitayama H, Takahashi C, Sato C, Noda M (2009) RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem 284:3461-3469
5. Noda M, Takahashi C (2007) Recklessness as a hallmark of aggressive cancer. Cancer Sci 98:1659-1665
6. Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, Kim HS, Dass CR, Choong PF (2011) RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer 117(15): 3517-3528
7. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN (1990) Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86:131-140
8. Gately S, Soff GA, Brem S (1995) The potential role of basic fibroblast growth factor in the transformation of cultured primary human fetal astrocytes and the proliferation of human glioma (U-87) cells. Neurosurgery 37:723-773 discussion 730-722
9. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133
10. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848
11. MacheinMR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109-120
12. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297-310
13. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
15. Ribatti D, Vacca A, Dammacco F (1999) The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1:293-302
16. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
17. Chaudhry IH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS (2001) Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409-415
18. Chen TC, Hinton DR, Yong VW, Hofman FM (1997) TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. J Neuroimmunol 73:155-161
19. Nico B, Crivellato E, Guidolin D, Annese T, Longo V, Finato N, Vacca A, Ribatti D (2010) Intussusceptive microvascular growth in human glioma. Clin Exp Med 10:93-98
20. Netto GC, Bleil CB, Hilbig A, Coutinho LM (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17-23
21. Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F (2009) Microvessel density and area in pituitary microadenomas. Endocr Pathol 20:221-226
22. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474-2484
23. Clark JC, Thomas DM, Choong PF, Dass CR (2007) RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 26:675-683
24. Rahmah NN, Sakai K, Nakayama J, Hongo K (2010) Reversioninducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg Rev 33:167-173 discussion 173
25. Miki T, Shamma A, Kitajima S, Takegami Y, Noda M, Nakashima Y, Watanabe K, Takahashi C (2010) The ss1-integrin-dependent function of RECK in physiologic and tumor angiogenesis. Mol Cancer Res 8:665-676
26. Chandana EP,Maeda Y, Ueda A, Kiyonari H, Oshima N, Yamamoto M, Kondo S, Oh J, Takahashi R, Yoshida Y, Kawashima S, Alexander DB, Kitayama H, Takahashi C, Tabata Y, Matsuzaki T, Noda M (2010) Involvement of the Reck tumor suppressor protein in maternal and embryonic vascular remodeling in mice. BMC Dev Biol 10:84
27. Song SY, Son HJ, Nam E, Rhee JC, Park C (2006) Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 42:101-108